Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management

Journal of Diabetes and its Complications

Volumn 31, Issue 3, 2017, Pages 611-614

  Kum Nji, Juliette Sandifer ^a   Gosmanov, Aidar R ^b   Steinberg, Helmut ^a   Dagogo Jack, Samuel ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b STRATTON VA MEDICAL CENTER   (United States)

Author keywords

Autoantibodies; C peptide; Diabetic ketoacidosis; Hyperglycemia; Insulinopenia; Sodium glucose cotransporter 2 inhibitors

Indexed keywords

3 HYDROXYBUTYRIC ACID; BICARBONATE; C PEPTIDE; CANAGLIFLOZIN; DAPAGLIFLOZIN; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INFUSION FLUID; INSULIN; INSULIN ASPART; INSULIN DETEMIR; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; THIAZIDE DIURETIC AGENT;

ABDOMINAL PAIN; ADULT; ANION GAP; ARTICLE; BEDTIME DOSAGE; BICARBONATE BLOOD LEVEL; CASE REPORT; CASE STUDY; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITAL READMISSION; HUMAN; HYPERGLYCEMIA; HYPERPHAGIA; HYPOINSULINEMIA; INTENSIVE CARE UNIT; KETONURIA; LABORATORY TEST; MALAISE; MALE; METABOLIC ACIDOSIS; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ADENOCARCINOMA; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RISK FACTOR; TREATMENT RESPONSE; VOMITING; WEAKNESS; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; COMBINATION DRUG THERAPY; COMPLICATION; DRUG MONITORING; DRUG RESISTANCE; METABOLISM;

ADULT; DIABETES MELLITUS, TYPE 2; DIABETIC KETOACIDOSIS; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; RISK FACTORS; SODIUM CHLORIDE SYMPORTER INHIBITORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85007390793     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.11.004     Document Type: Article

References (16)

1. Basu, A., Close, C.F., Jenkins, D., Krentz, A.J., Nattrass, M., Wright, A.D., Persisting mortality in diabetic ketoacidosis. Diabetic Medicine 10:3 (1993), 282–284.
2. Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J.,.. Pattou, F., Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nature Medicine 21:5 (2015), 512–517.
3. Cohen, J.J., Berglund, F., Lotspeich, W.D., Renal tubular reabsorption of acetoacetate, inorganic sulfate and inorganic phosphate in the dog as affected by glucose and phlorizin. The American Journal of Physiology 184:1 (1956), 91–96.
4. Erondu, N., Desai, M., Ways, K., Meininger, G., Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38:9 (2015), 1680–1686.
5. FDA Drug Safety Communication, FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections [internet]. 15 May 2015. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm (Accessed 15 January 2016).
6. Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T.,.. Woerle, H.J., Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of Clinical Investigation 124:2 (2014), 499–508.
7. Handelsman, Y., Henry, R.R., Bloomgarden, Z.T., Dagogo-Jack, S., DeFronzo, R.A., Einhorn, D., et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of Sglt-2 inhibitors and diabetic ketoacidosis. Endocrine Practice 22:6 (2016), 753–762, 10.4158/EP161292.PS.
8. Hayami, T., Kato, Y., Kamiya, H., Kondo, M., Naito, E., Sugiura, Y.,.. Nakamura, J., Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. Journal of Diabetes Investigation 6:5 (2015), 587–590.
9. Kaku, K., Watada, H., Iwamoto, Y., Utsunomiya, K., Terauchi, Y., Tobe, K.,.. Tofogliflozin 003 Study Group, Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: A combined phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovascular Diabetology, 13, 2014, 65.
10. Kurosaki, E., Ogasawara, H., Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data. Pharmacology & Therapeutics 139:1 (2013), 51–59.
11. Lin, M.V., Bishop, G., Benito-Herrero, M., Diabetic ketoacidosis in type 2 diabetics: A novel presentation of pancreatic adenocarcinoma. Journal of General Internal Medicine 25:4 (2010), 369–373.
12. Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T.V., Tripathy, D.,.. DeFronzo, R.A., Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. The Journal of Clinical Investigation 124:2 (2014), 509–514.
13. Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38:9 (2015), 1687–1693.
14. Rosenstock, J., Ferrannini, E., Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38:9 (2015), 1638–1642.
15. Storgaard, H., Bagger, J.I., Knop, F.K., Vilsboll, T., Rungby, J., Diabetic ketoacidosis in a patient with type 2 diabetes after initiation of sodium-glucose cotransporter 2 inhibitor treatment. Basic & Clinical Pharmacology & Toxicology. 118:2 (2016), 168–170.
16. Umpierrez, G.E., Cuervo, R., Karabell, A., Latif, K., Freire, A.X., Kitabchi, A.E., Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care 27:8 (2004), 1873–1878.